Йодрезистентный рак щитовидной железы: патогенез и подходы к лечению

Автор: Авилов О.Н., Солодкий В.А., Фомин Д.К., Измайлов Т.Р.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 4 т.17, 2017 года.

Бесплатный доступ

В обзоре представлены современные литературные данные патогенеза йодрезистентного рака щитовидной железы, с подробным описанием молекулярно-генетических исследований, в том числе и основных факторов ангиогенеза. Отражены существующие методы диагностики и лечения пациентов с верифицированным йодрезистентным раком щитовидной железы. Показаны преимущества проведения многокомпонентного лечения, включающего хирургическое вмешательство, радиойодтерапию и химиотерапевтическое лечение таргетными препаратами у данной когорты пациентов.

Йодрезистентный рак щитовидной железы, радиойодтерапия

Короткий адрес: https://sciup.org/14955558

IDR: 14955558

Список литературы Йодрезистентный рак щитовидной железы: патогенез и подходы к лечению

Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена  филиал ФГБУ «НМИРЦ» Минздрава России. 2017. 250 с.
Румянцев П.О. Рефрактерность высокодифференцированного рака щитовидной железы к лечению радиоактивным йодом. Опухоли головы и шеи. 2013. Т. 3. С. 11-15.
Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи. 2014. Т. 3. С. 4-9.
Pellegriti G., Frasca F., Regalbuto C., et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013.
Haugen B.R., Alexander E.K., Bible K. C., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016. V. 26. T. 1. P. 1-133.
Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006. V. 91. N. 8. P. 2892-2899.
Schlumberger M., Brose M., Elisei R., et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014. V. 2. T. 5. P. 356-358
Sacks W., Braunstein G. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract. 2014. V. 20. N. 3. P. 263-275.
Wang W., Larson S.M., Tuttle R.M., et al. Resistance of -fluorodeoxyglucose-avid metastatic Thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001. V. 11. N. 12. P. 1169-1175.
Xing M., Haugen B., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013. V. 381. N. 9871. P. 1058-1069.
Nixon I.J., Whitcher M.M., Palmer F.L., et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012. V. 22. P. 884-889.
Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006. V. 91. N. 8. P. 2892-2899.
Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006. V. 91. N. 2. P. 498-505.
Spitzweg C., Bible K.C., Hofbauer L.C., Morris J.C. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014. V. 2. N. 10. P. 830-842.
Spitzweg C., Harrington K.J., Pinke L.A., et al. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001. V. 86. P. 3327-3335.
Spitzweg C., Morris J.C. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf). 2002. V. 57. N. 5. P. 559-574.
M. Xing. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013. V. 13. N. 3. P. 184-199.
Haugen B.R., Sherman S.I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013.V. 34. N. 3. P. 439-455.
M Xing. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007. V. 148. N. 3. P. 948-953.
Dai G., Levy O., Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996. V. 379. N. 6564. P. 458-460.
Smanik P.A., Liu Q., Furminger T.L., et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun. 1996. V. 226. N. 2. P. 339-345.
Smanik P.A., Ryu K.Y, Theil K.S., et al. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology. 1997.V. 138. N.8. P. 3555-3558.
Hingorani M., Spitzweg C., Vassaux G., et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010.V. 10. N.2. P. 242-267.
Riedel C., Levy O., Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem. 2001. V. 276. N. 24. P. 21458-21463.
Seidlin S.M., Marinelli L.D., Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. Am Med Assoc. 1946. V. 132. N. 14. P. 838-847.
De Vita G., Zannini M., Cirafici A.M., et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ. 1998.V. 9. N. 1. P. 97-103.
Portella G., Vitagliano D., Borselli C., et al. Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res. 1999. V. 11. N. 9. P. 421-427.
Durante C., Puxeddu E., Ferretti E., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007. V. 92. N. 7. P. 2840-2843.
Knauf J.A., Kuroda H., Basu S., Fagin, J.A. RET/PTC-induced dedifferation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003. V.22. P. 4406-4412.
Venkataraman G.M., Yatin M., Marcinek R., Ain K.B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab. 1999. V. 84. N. 7. P. 2449-2457.
Xing M., Usadel H., Cohen Y., et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 2003. V. 63. P. 2316-2321.
Furuya F., Shimura H., Suzuki H., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology. 2004. V. 145. N. 6. P. 2865-2875.
Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na+/I-symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2001.V.86. N. 7. P. 3430-3435.
Puppin C., D'Aurizio F., D'Elia A.V., et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology. 2005. V. 146. N. 9. P. 3967-3974.
Hou P., Bojdani E., Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab. 2010. V.95. N. 2. P. 820-828.
Gottlieb J.A., Hill C.S. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974. V. 290. N. 4. P. 193-197.
Colevas A., Shah M. Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists. Am Soc Clin Oncol Educ Book. 2012. P. 384-388.
Shimaoka K., Schoenfeld D., Dewys W., et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985. V. 56. N.9. P. 2155-2160.
Matuszczyk A., Petersenn S., Bockisch A., al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008. V. 40. N. 3. P. 210-213.
Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014. V. 6. N. 6. P. 267-279.
Bunone G., Vigneri P., Mariani L., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999. V. 155. N. 6. P. 1967-1976.
Klein M., Vignaud J., Hennequin V., et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001. V. 86. N. 2. P. 656-658.
Homsi J., Daud A. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007. V. 14. N. 3. P. 285-294.
Saez J. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer. Anticancer Agents Med Chem. 2013.V.13. N. 3. P. 483-495.
Sacks W., Braunstein G. D. Evolving approaches in managing radioactive iodinerefractory differentiated thyroid cancer. Endocr Pract. 2014. V.20. N. 3. P. 236-275.
Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008. V. 7. N. 10. P. 3129-3140.
Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009. V. 27. N. 10. P. 1675-1684.
Matsui J., Yamamoto Y., Funahashi Y., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008. V. 122. N. 3. P. 664-671.
Okamoto K., Kodama K., Takase K., et al. Antitumor activities of the targeted multityrosine kinase inhibitor lenvatinib (e7080) against ret gene fusion-driven tumor models. Cancer Lett. 2013. V. 340. N. 1. P. 97-103.
Hoftijzer H., Heemstra K.A., Morreau H., et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009. V. 161. N. 6. P. 923-931.
Brose M.S., Frenette C.T., Keefe S.M., Stein S.M. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol. 2014.V. 41(Suppl. 2). P. S1-S16.
Ho A., Grewal R., Leboeuf R., et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013. V. 368. N. 7. P. 623-632.
Sacks W., Braunstein G.D. Evolving approaches in managing radioactive iodinerefractory differentiated thyroid cancer. Endocr Pract. 2014. V.20. N. 3. P. 263-75.
Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014. V. 6. N. 6. P. 267-279.
Ahmed M., Barbachano Y., Riddell A., et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011. V. 165. N. 2. P. 315-322.
Schreinemakers J.M., Vriens M.R., Munoz-Perez N., et al. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol. 2012. V. 10. P. 192.
Schlumberger M., Tahara M., Wirth L., Robinson B., Brose M., Elisei R., et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with131-I-refractory differentiated thyroid cancer (SELECT) . Paper presented at American Society of Clinical Oncology, Chicago, IL, 30 May-3 June 2013. 2013.
Saito, T, Endo, T, Kawaguchi, A et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest. 1998. V. 101. P. 1296-1300.

Еще

Статья научная